APA (7th ed.) Citation

A, R., LB, S., M, M., S, O., GP, A., J, G., & PB, W. (2014). Causality assessment for suspected DILI during clinical phases of drug development. Drug safety, 37 Suppl 1, S47. https://doi.org/10.1007/s40264-014-0185-4

Chicago Style (17th ed.) Citation

A, Regev, Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, and Watkins PB. "Causality Assessment for Suspected DILI During Clinical Phases of Drug Development." Drug Safety 37 Suppl 1 (2014): S47. https://doi.org/10.1007/s40264-014-0185-4.

MLA (9th ed.) Citation

A, Regev, et al. "Causality Assessment for Suspected DILI During Clinical Phases of Drug Development." Drug Safety, vol. 37 Suppl 1, 2014, p. S47, https://doi.org/10.1007/s40264-014-0185-4.